Latest News

STAT Plus: Regeneron, with a new drug, tries to elbow its way into a crowded immunotherapy market

Regeneron Pharmaceuticals (REGN) has won Food and Drug Administration approval for a new cancer therapy, lining up behind five marketed treatments that work by removing brakes on the immune system to turn the body’s defenses against tumors.

The company, alongside partner Sanofi (SNY), is entering a crowded market in which it is years behind the leaders, who have reaped billions of dollars in sales while racking up FDA approvals in more than a dozen tumor types. But Regeneron believes that, with some clever positioning and combination treatments, it can outfox its rivals and build its drug, cemiplimab, into a contender in the field.

Continue to STAT Plus to read the full story…

Source link

Related posts

Outcome Capital Announces Meridian Bioscience Has Acquired GenePOC


Workload and burnout contribute to unhealthy behaviors that cause weight gain


Opinion: Quitting smoking is hard. Mindfulness hacks the habit loop, offering a new approach


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy